Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NurExone Biologic ( (TSE:NRX) ) has provided an announcement.
NurExone Biologic Inc. is expanding its presence in the U.S. market by presenting at the International Society for Cell & Gene Therapy 2025 Annual Meeting. The company will showcase its ExoPTEN therapy, which has shown promise in preclinical trials for spinal cord injuries. This presentation is part of their strategy to increase visibility and stakeholder value, supported by the recent launch of its U.S. subsidiary, Exo-Top, aimed at enhancing their footprint in the biotech industry.
More about NurExone Biologic
NurExone Biologic Inc. is a biotech company listed on the TSX Venture Exchange, OTCQB, and Frankfurt, specializing in regenerative exosome-based therapies for central nervous system injuries. Its flagship product, ExoPTEN, is positioned for treating spinal cord and optic nerve injuries, targeting significant market opportunities. The company has established a U.S. subsidiary, Exo-Top, to focus on producing and supplying GMP exosomes for research and therapeutic use.
Average Trading Volume: 43,466
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$33.85M
Find detailed analytics on NRX stock on TipRanks’ Stock Analysis page.